Utility of autologous fibrin glue for prevention of delayed bleeding of gastric endoscopic submucosal dissection under antithrombotic therapy

Utility of autologous fibrin glue for prevention of delayed bleeding of gastric endoscopic submucosal dissection under antithrombotic therapy - T-HOPE 1306

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000019386

Enrollment

Registered

2015-10-16

Start date

2013-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric neoplasms

Interventions

autologous fibrin glue

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. patients over 20 years old 2. patients with gastric neoplasms indicated for the treatment of ESD 3. patients under antithrombotic therapy 4. patients with written informed consent

Exclusion criteria

Exclusion criteria: 1. Hb<11g/dl 2. patients with active infections disease 3. patients under severe dehydration condition 4. patients with allergy for bovine product 5. patients taking antiplasmin agent 6. Patients were excluded if they were considered inappropriate for participation in this study by their attending physician.

Design outcomes

Primary

Measure	Time frame
rate of delayed bleeding	—

Secondary

Measure	Time frame
adverse event of autologous fibrin glue rate of allogeanic blood transfusion rate of autologous blood transfusion condition of ESD ulcer and fibrin glue on 1POD, 7POD, and 8 week.	—

Countries

Japan

Contacts

Public ContactDaisuke Kikuchi

Toranomon hospital Department of gastroenterology

dkiku1230@gmail.com+81-33588-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026